Intranasal delivery of paroxetine nanoemulsion via the olfactory region for the management of depression: Formulation, behavioural and biochemical estimation

Nanotechnology

Volumn 27, Issue 2, 2016, Pages

  Pandey, Yogendra Raj ^a   Kumar, Shobhit ^a   Gupta, Bijay Kumar ^a   Ali, Javed ^a   Baboota, Sanjula ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

behavioural studies; biochemical estimation; intranasal administration; nanoemulsion; paroxetine; spontaneous emulsification

Indexed keywords

BIOCHEMISTRY; DROPS; DRUG PRODUCTS; EMULSIFICATION; POLYDISPERSITY; PROPYLENE; RATS; SURFACE ACTIVE AGENTS; VISCOSITY; ZETA POTENTIAL;

BEHAVIOURAL STUDIES; INTRANASAL; NANOEMULSION; PAROXETINE; SPONTANEOUS EMULSIFICATION;

REFRACTIVE INDEX;

ANTIDEPRESSANT AGENT; EMULSION; PAROXETINE;

ANIMAL; ANIMAL BEHAVIOR; DEPRESSION; DISEASE MODEL; DRUG EFFECTS; EMULSION; FEMALE; INTRANASAL DRUG ADMINISTRATION; MALE; MEDICINAL CHEMISTRY; PARTICLE SIZE; PIG; PROCEDURES; RAT; WISTAR RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ANIMAL; CHEMISTRY, PHARMACEUTICAL; DEPRESSION; DISEASE MODELS, ANIMAL; EMULSIONS; FEMALE; MALE; PAROXETINE; PARTICLE SIZE; RATS; RATS, WISTAR; SWINE;

EID: 85043810717     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/27/2/025102     Document Type: Article

References (36)

1. Singh A R and Singh S A 2004 Towards a suicide free society: identify suicide prevention as public health policy Mens Sana Monogr. 2 21-33
2. Michel T M, Pülschen D and Thome J 2012 The role of oxidative stress in depressive disorders Curr. Pharm. Des. 18 5890-9
3. Salim S 2014 Oxidative stress and psychological disorders Curr. Neuropharmacol. 12 140-7
4. Kaludercic N, Mialet-Perez J, Paolocci N, Parini A and Di Lisa F 2014 Monoamine oxidases as sources of oxidants in the heart J. Mol. Cell. Cardiol. 73 34-42
5. Hiemke C and Härtter S 2000 Pharmacokinetics of selective serotonin reuptake inhibitors Pharmacol. Ther. 85 11-28
6. Alam M I, Beg S, Samad A, Baboota S, Kohli K, Ali J, Ahuja A and Akbar M 2010 Strategy for effective brain drug delivery Eur. J. Pharm. Sci. 40 385-403
7. Alam M I, Baboota S, Ahuja A, Ali M, Ali J and Sahni J K 2013 Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood Drug Deliv. 20 247-51
8. Mustafa G, Ahuja A, Al Rohaimi A H, Muslim S, Hassan A A, Baboota S and Ali J 2015 Expert Rev. Neurother. 15 695-710
9. Alam M I, Baboota S, Ahuja A, Ali M, Ali J, Sahni J K and Bhatnagar A 2014 Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug Int. J. Pharm. 470 99-106
10. Ganta S, Deshpande D, Korde A and Amiji M 2010 A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers Mol. Membr. Biol. 27 260-73
11. Mason T G, Wilking J N, Meleson K, Chang C B and Graves S M 2006 Nanoemulsions: formation, structure, and physical properties J. Phys.: Condens. Matter 18 R635-66
12. Belhaj N, Dupuis F, Arab-Tehrany E, Denis F M, Paris C, Lartaud I and Linder M 2012 Formulation, characterization and pharmacokinetic studies of coenzyme Q10 PUFA's nanoemulsions Eur. J. Pharm. Sci. 47 305-12
13. Bazylinska U, Kulbacka J and Wilk K A 2014 Dicephalic ionic surfactants in fabrication of biocompatible nanoemulsions: factors influencing droplet size and stability Colloids Surf. A 460 312-20
14. Sharma S, Sahni J K, Ali J and Baboota S 2015 Effect of high-pressure homogenization on formulation of TPGS loaded nanoemulsion of rutin - pharmacodynamic and antioxidant studies Drug Deliv. 22 541-51
15. Choudhury H, Gorain B, Karmakar S, Biswas E, Dey G, Barik R, Mandal M and Pal T K 2014 Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform Int. J. Pharm. 460 131-43
16. Shakeel F, Baboota S, Ahuja A, Ali J, Aqil M and Shafiq S 2007 Nanoemulsions as vehicles for transdermal delivery of aceclofenac AAPS PharmSciTech. 8 191-9
17. Pangeni R, Sharma S, Mustafa G, Ali J and Baboota S 2014 Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress Nanotechnology 25 485102
18. Mayer S, Weiss J and McClements D J 2013 Vitamin E-enriched nanoemulsions formed by emulsion phase inversion: factors influencing droplet size and stability J. Colloid Interface Sci. 402 122-30
19. Bahadur S and Pathak K 2012 Buffered nanoemulsion for nose to brain delivery of ziprasidone hydrochloride: preformulation and pharmacodynamic evaluation Curr. Drug Deliv. 9 596-607
20. Alam M I, Baboota S, Ahuja A, Ali M, Ali J and Sahni J K 2012 Intranasal administration of nanostructured lipid carriers containing CNS acting drug: pharmacodynamic studies and estimation in blood and brain J. Psychiatr. Res. 46 1133-8
21. Haque S, Md S, Sahni J K, Ali J and Baboota S 2014 Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression J. Psychiatr. Res. 48 1-12
22. Lee H, Ohno M, Ohta S and Mikami T 2013 Regular moderate or intense exercise prevents depression-like behavior without change of hippocampal tryptophan content in chronically tryptophan-deficient and stressed mice PLoS One 8 e66996
23. Kamal S M 2014 Hepatic antioxidant effect of paroxetine in rats exposed to chronic restraint model Br. J. Med. Med. Res. 4 2611-20
24. Boyne A F and Ellman G L 1972 A methodology for analysis of tissue sulfhydryl components Anal. Biochem. 46 639-53
25. Ohkawa H, Ohishi N and Yagi K 1979 Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction Anal. Biochem. 95 351-8
26. Burg A, Silberstein T, Yardeni G, Tavor D, Blumenfeld J, Zilbermann I and Saphier O 2010 Role of radicals in the lipid peroxidation products of commercial infant milk formula J. Agric. Food Chem. 58 2347-50
27. Bhavna M S, Ali M, Ali R, Bhatnagar A, Baboota S and Ali J 2014 Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation Int. J. Biol. Macromol. 67 418-25
28. Prajapati H N, Dalrymple D M and Serajuddin A T 2012 A comparative evaluation of mono-, di- and triglyceride of medium chain fatty acids by lipid/surfactant/water phase diagram, solubility determination and dispersion testing for application in pharmaceutical dosage form development Pharm. Res. 29 285-305
29. Singh A K, Chaurasiya A, Awasthi A, Mishra G, Asati D, Khar R K and Mukherjee R 2009 Oral bioavailability enhancement of exemestane from self-microemulsifying drug delivery system (SMEDDS) AAPS PharmSciTech. 10 906-16
30. Preetz C, Hauser A, Hause G, Kramer A and Mäder K 2010 Application of atomic force microscopy and ultrasonic resonator technology on nanoscale: distinction of nanoemulsions from nanocapsules Eur. J. Pharm. Sci. 39 141-51
31. Polychniatou V and Tzia C 2014 Study of formulation and stability of co-surfactant free water-in-olive oil nano- and submicron emulsions with food grade non-ionic surfactants J. Am. Oil Chem. Soc. 91 79-88
32. Sakane T, Akizuki M, Yamashita S, Nadai T, Hashida M and Sezaki H 1991 The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug Chem. Pharm. Bull. 39 2456-8
33. Engleman E A, Perry K W, Mayle D A and Wong D T 1995 Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor Neuropsychopharmacology 12 287-95
34. Detke M J, Rickels M and Lucki I 1995 Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants Psychopharmacology 121 66-72
35. Palta P, Samuel L J, Miller E R and Szanton S L 2014 Depression and oxidative stress: results from a meta-analysis of observational studies Psychosom. Med. 76 12-9
36. Chung Y C, Kim S R and Jin B K 2010 Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease J. Immunol. 185 1230-7